Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Correction to: Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
|
31414301 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data justify to explore combined targeted therapy approaches in glioblastoma that aim at down-regulating AKT function to enhance the therapeutic potential of dual PI3K/mTOR inhibitors.
|
31618458 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed the expression and activity of PRMT5 in response to mTOR inhibition in GBM cell lines and short-term patient cultures.
|
31473880 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety.
|
31541850 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we show that in the highly lethal brain tumor glioblastoma (GBM), mechanistic target of rapamycin complex 2 (mTORC2), a critical core component of the growth factor signaling system, couples acetyl-CoA production with nuclear translocation of histone-modifying enzymes including pyruvate dehydrogenase (PDH) and class IIa histone deacetylases (HDACs) to globally alter histone acetylation.
|
31712311 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
CTD_human |
Identification of recurrent fusion genes across multiple cancer types.
|
30705370 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
|
30771196 |
2019 |
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>Abbreviations</b>: AKT1: AKT serine/threonine kinase 1; ATG14: autophagy related 14; BECN1: Beclin 1; DDR1: discoidin domain receptor tyrosine kinase 1; ECM: extracellular matrix; GBM: glioblastoma multiforme; MTOR: mechanistic target of rapamycin kinase; PDGFR: platelet derived growth factor receptor; PIK3C3: phosphatidylinositol 3-kinase catalytic subunit type 3; RPTOR: regulatory associated protein of MTOR complex 1; RICTOR: RPTOR independent companion of MTOR complex 2.
|
31117874 |
2019 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we analyzed the rationale of targeting mTOR in GBM and the available preclinical and clinical evidence supporting the choice of this therapeutic approach, highlighting the different roles of mTORC1 and mTORC2 in GBM biology.
|
30662577 |
2018 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mitogen-activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)-dependent signaling are hallmarks of glioblastoma.
|
29313954 |
2018 |
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Rictor has been demonstrated to result in increased mechanistic target of rapamycin C2 (mTORC2) nucleation and activity leading to tumor growth and increased invasive characteristics in glioblastoma multiforme (GBM).
|
29059166 |
2018 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma.
|
29126203 |
2018 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aims to explore the role of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway and its relationship with hypoxia inducible factor-1α (HIF-1α) in the migration and invasion of human glioblastoma U87 cells under hypoxia.
|
30371540 |
2018 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
As aggressive invasion and migration of tumors are associated with mesenchymal and stem-like cell properties, this study aimed to examine the effect of mammalian target of rapamycin inhibitors on these features in glioblastoma cells.
|
28351321 |
2017 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study showed that hemodynamic abnormalities of glioblastoma were associated with genomics activation status of mTOR-EGFR pathway, however, the radiogenomics associations are different in enhancing and peri-enhancing area of glioblastoma.
|
28889246 |
2017 |
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The present study improves our awareness of basic mechanisms which relate mTOR activity to the biology of glioblastoma cells.
|
28418837 |
2017 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among several activities, mTOR-induced autophagy suppression is key in GBM malignancy.
|
29259984 |
2017 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Downregulation of AKAP1 impaired mTOR pathway and inhibited glioblastoma growth.
|
28569781 |
2017 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to new mTOR targets, which may have a plant origin form, more potent mTOR inhibitors by utilizing the computational methodology may emerge as a hope for GBM therapy.
|
26341051 |
2016 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that C11 also blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-GBM properties when combined with the mechanistic target of rapamycin kinase inhibitor PP242.
|
27226604 |
2016 |
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of GLS following mTOR inhibitor treatment promoted GBM survival in an α-ketoglutarate-dependent (αKG-dependent) manner.
|
25798620 |
2015 |
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Concurrent inhibition of mTOR and ribosomal protein s6 activity may underlie the inhibition of GBM proliferation by PKI.
|
23110505 |
2013 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
|
23440206 |
2013 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have investigated mTOR signaling in glioma cells with the allosteric mTORC1 inhibitor rapamycin, the mTORC1/2 inhibitor Ku-0063794, a dual PI3K/mTORC1/2 kinase inhibitor PI-103, and siRNA against raptor, rictor, or mTOR, and evaluated the value of mTOR inhibitors for the treatment of glioblastoma.
|
22125077 |
2012 |
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors.
|
22015553 |
2012 |